Nkarta announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul Hastings, who continues in his role as CEO. Additionally, Nkarta has broadened the role of David Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Hastings. The company expects to announce preliminary data from the Ntrust-1 and Ntrust-2 clinical trials data in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Nkarta Advances Clinical Trials and Explores New Treatments
- Nkarta initiates trial of NKX019 in lupus nephritis
- Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
- Nkarta’s Annual Meeting Results in Key Corporate Decisions
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors